核查意见 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 使用自有资金进行委托理财的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为华兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公司"）首次公开 发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等规定，对华兰疫苗拟使 用自有资金进行委托理财的事项进行了审慎尽职调查，具体核查情况如下： 一、投资概况 （一）投资目的 公司自有资金。 1 （三）投资额度及期限 不超过 35 亿元（含 35 亿元）的自有资金，在不超过上述额度范围内，资金 可以滚动使用，期限自公司 2024 年度股东大会审议通过之日起至 2025 年度股东 大会召开之日止。 最大限度地提高公司短期自有资金的使用效率，为公司和股东谋取较好的投 资回报。 （四）资金来源 （二）投资范围 国债、债券、货币市场基金、质押式国债回购、券商收益权凭证、券商收益 权转让、深交所/上交所报价回购、银行结构性理财产品、券商资产管 ...

安徽承义律师事务所 法律意见书 安徽承义律师事务所 关于华兰生物疫苗股份有限公司 2022 年限制性股票激励计划首次授予第二个归属期 及预留授予第一个归属期归属条件未成就暨 作废部分已授予但尚未归属的限制性股票 相关事项的法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 法律意见书 关于华兰生物疫苗股份有限公司 2022 年限制性股票激励计划首次授予第二个归属期 释 义 在本法律意见书中，除非文义另有所指，下列词语具有下述含义： | 本所 | 指 | 安徽承义律师事务所 | | --- | --- | --- | | 本律师 | 指 | 本所为本激励计划指派的经办律师，即在本法律意见书签 | | | | 署页"经办律师"一栏中签名的律师 | | 华兰疫苗/上市公司/公 | 指 | 华兰生物疫苗股份 ...

华兰生物疫苗股份有限公司 内部控制审计报告 大华内字[2025]0011000015 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 华兰生物疫苗股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 内部控制审计报告 1-2 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 大华内字[2025]0011000015 号 华兰生物疫苗股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了华兰生物疫苗股份有限公司（以下简称华兰疫苗） 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定 ...

华兰生物疫苗股份有限公司 募集资金存放与使用情况鉴证报告 大华核字[2025]0011000311 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 华兰生物疫苗股份有限公司 募集资金存放与使用情况鉴证报告 （2024 年度） 目 录 页 次 一、 募集资金存放与使用情况鉴证报告 1-2 二、 华兰生物疫苗股份有限公司 2024 年度募集资 金存放与使用情况的专项报告 1-7 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 (10) 5835 0011 传真：86 (10) 5835 0006 www.dahua-cpa.com 募 集 资 金 存 放 与 使 用 情 况 鉴 证 报 告 大华核字[2025]0011000311 号 华兰生物疫苗股份有限公司全体股东： 我们审核了后附的华兰生物疫苗股份有限公司（以下简称华兰疫 苗）《2024 年度募集资金存放与使用情况的专项报告》（以下简称 "募集 ...

内部控制自我评价报告的核查意见 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2024 年度内部控制自我评价报告的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为华 兰生物疫苗股份有限公司（以下简称"华兰疫苗"、"公司"或"发行人"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等文件的要求，华泰联合对华兰疫苗 2024 年度内部控制制度等相关事项进行核 查，并发表独立意见如下： 一、华兰疫苗内部控制的基本情况 （一）内部控制评价范围 公司按照风险导向原则确定纳入评价范围的主要单位、业务和事项以及高风 险领域。 纳入评价范围的公司包括公司本部及下属子公司，纳入评价范围单位资产占 公司合并财务报表资产总额的 100%，营业收入合计占公司合并财务报表营业收 入总额的 100%。 纳入评价范围的主要业务和事项包括: 组织结构、公司治理、发展战略、人 力资源政策、公司对子公司的内部控制、关联交易的内部控制、财务报告、对外 担保控制、对外投资控制、信息披露管理等。 （二 ...

华兰生物疫苗股份有限公司 审计报告 大华审字[2025]0011001096 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified Public Accountants（Special General Partnership） 华兰生物疫苗股份有限公司 审计报告及财务报表 （2024 年 1 月 1 日至 2024 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-8 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-82 | 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号 ...

现场检查报告 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司 2024 年现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关法律法规的要求，华泰联合 证券有限责任公司作为华兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公 司"）首次公开发行股票并在创业板上市的保荐人，于 2025 年 3 月 17 日对华兰 疫苗 2024 年有关情况进行了现场检查，报告如下： | 保荐人名称：华泰联合证券有限责任公司 被保荐公司简称：华兰疫苗 | | | | --- | --- | --- | | 保荐代表人姓名：贾鹏 联系电话：010-56839300 | | | | 保荐代表人姓名：刘晓宁 联系电话：010-56839300 | | | | 现场检查人员姓名：贾鹏、左宝祥、张信远 | | | | 现场检查对应期间：2024 年度 | | | | 现场检查时间：2025 年 3 月 17 日 | | | | 一、现场检查事项 现场检查意见 | | | | （一）公司治理 是 | 否 | 不适 | | | | 用 | | 现场检查手段 ...

一、募集资金基本情况 根据中国证券监督管理委员会《关于同意华兰生物疫苗股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕2 号），华兰生物疫苗股份有限公司 （以下简称"公司"）获准向社会公开发行人民币普通股（A 股）股票 4,001.00 万 股，每股面值人民币 1 元，发行价格为人民币 56.88 元/股，募集资金总额为人民 币 2,275,768,800.00 元，扣除各项发行费用人民币 31,565,696.07 元（含税），实 际募集资金净额为人民币 2,244,203,103.93 元，上述募集资金已于 2022 年 2 月 14 日划至公司指定账户。大华会计师事务所（特殊普通合伙）已于 2022 年 2 月 14 日对公司首次公开发行股票的资金到位情况进行了审验，并出具了《验资报 告》（大华验字[2022]000066 号）。 核查意见 华泰联合证券有限责任公司 关于华兰生物疫苗股份有限公司部分募投项目结项并将节 余募集资金投入其他募投项目的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为华兰生物疫苗股份有限公司（以下简称"华兰疫苗"或"公司"）首次 ...

Financial Performance - The company's operating revenue for 2024 was ¥1,127,812,323.85, a decrease of 53.21% compared to ¥2,410,428,457.20 in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥205,515,315.75, down 76.10% from ¥859,968,598.42 in 2023[21]. - The cash flow from operating activities for 2024 was ¥468,041,442.48, a decline of 47.29% compared to ¥888,024,961.36 in 2023[21]. - The basic earnings per share for 2024 was ¥0.3436, a decrease of 76.00% from ¥1.4316 in 2023[21]. - The total assets at the end of 2024 were ¥7,523,255,843.58, down 5.90% from ¥7,995,318,297.21 at the end of 2023[21]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a decrease of 84.12% to ¥120,390,566.59 in 2024 from ¥757,997,173.80 in 2023[21]. - The company is experiencing uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the last three accounting years[21]. - The company's total revenue for 2024 was approximately ¥1.13 billion, a decrease of 53.21% compared to ¥2.41 billion in 2023[47]. - Vaccine products accounted for 99.59% of total revenue in 2024, with a revenue of approximately ¥1.12 billion, down 53.34% from ¥2.41 billion in 2023[47]. - The influenza vaccine generated approximately ¥1.07 billion in revenue, representing 95.14% of total revenue from vaccine products, a decline of 55.34% year-over-year[48]. Market Conditions and Risks - The company's performance in 2024 significantly declined due to multiple factors, including a decrease in flu vaccine prices, fluctuations in vaccination rates, and a drop in market demand, with many vaccine companies reporting a decline of over 50% in their annual performance[5]. - Despite the challenging market environment, the company does not foresee significant risks to its ongoing operations, as there is no indication of overcapacity or sustained decline in the industry[5]. - The company has detailed potential risks in its report, which investors should review to understand the differences between plans, forecasts, and commitments[6]. - The overall trend of performance fluctuations aligns with the broader industry trends, as multiple domestic vaccine companies have experienced similar challenges[5]. - The competitive landscape for quadrivalent influenza vaccines is intensifying, with price reductions from multiple manufacturers potentially affecting market share and profitability[84]. - The company faces risks related to its product structure being relatively singular, with over 90% of revenue coming from influenza vaccines, which could impact profitability if market conditions change[82]. - The company faces risks in vaccine development due to lengthy approval processes and potential delays that could impact revenue generation[83]. Research and Development - The company continues to focus on research and development of new products and technologies to enhance its market position[5]. - The company is actively developing an mRNA vaccine research platform to prepare for future technological advancements in vaccine development[42]. - Research and development expenses increased by 78.51% to approximately ¥162.64 million, primarily due to increased clinical trial costs[56]. - The company has ongoing clinical research and registration for several vaccines, including a four-valent influenza vaccine and a rabies vaccine, with plans to expand its product pipeline[43]. - The company has established several core technology platforms to enhance vaccine research and production capabilities, aiming to mitigate product development risks[84]. Product Development and Market Strategy - The company has obtained drug registration certificates for various vaccines, including the quadrivalent influenza vaccine and the recombinant hepatitis B vaccine, establishing a strong position in the influenza vaccine sector[34]. - The company is preparing for production registration of the freeze-dried ACYW135 meningococcal polysaccharide vaccine, which has completed Phase III clinical trials[37]. - The company plans to reduce the price of the quadrivalent influenza vaccine by approximately 30% in June 2024 to enhance market competitiveness and accessibility[36]. - The company aims to improve the efficiency of fund utilization, achieving a usage rate of 56.31% for the raised funds[69]. - The company plans to enhance its marketing network to support the sales of existing products and the market introduction of new products, emphasizing the need for a more professional sales team[80]. - The company is focusing on expanding its market presence and enhancing its product offerings through new technology development[99]. Governance and Compliance - The company maintains a commitment to transparency and accuracy in its financial reporting, as affirmed by its board and management[5]. - The company has established a comprehensive internal control system and has maintained effective financial reporting internal controls with no significant deficiencies identified during the reporting period[133]. - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2024, with a standard unqualified opinion issued[137]. - The company has a strong governance structure, ensuring compliance with legal requirements and protecting shareholder interests[91]. - The company has implemented a transparent process for recommending board candidates, ensuring no interference in personnel decisions made by the board and shareholders[95]. Shareholder Engagement and Remuneration - The company plans to implement a stock repurchase program to stabilize its stock price within three years of its IPO, with a maximum repurchase amount not exceeding 30% of the previous year's audited net profit attributable to shareholders[156]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 192.77 million RMB[111]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation to company performance[131]. - The company ensured that minority shareholders had sufficient opportunities to express their opinions and that their rights were adequately protected[127]. - The company held its annual general meeting with an investor participation rate of 83.30% on April 19, 2024, and a temporary shareholders' meeting with a participation rate of 81.15% on August 9, 2024[97]. Social Responsibility and Community Engagement - The company emphasizes the integration of economic and social benefits, aiming for harmonious development with society while ensuring shareholder returns[144]. - The company actively engages in social responsibility initiatives, including targeted assistance in rural revitalization efforts[146]. - The company is committed to maintaining high standards in quality assurance and regulatory compliance in its operations[104]. - The company has pledged to continue its commitment to public welfare and community support as part of its operational strategy[144].